Premium
Soluble CD 44 and CD 44v6 and prognosis in children with B ‐cell acute lymphoblastic leukemia
Author(s) -
Amirghofran Zahra,
Asiaee Elham,
Kamazani Fatemeh M
Publication year - 2016
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12268
Subject(s) - cd44 , lymphoblastic leukemia , medicine , white blood cell , gastroenterology , leukemia , cell , chemistry , biochemistry
Abstract Aim CD 44v6 is an isoform of CD 44 that can be present in soluble form (s CD 44v6). The aim of this study is to evaluate the presence of soluble CD 44 (s CD 44) and s CD 44v6 in serum of children with B ‐cell precursor acute lymphoblastic leukemia ( B ‐ ALL ) and their relationship with prognosis. Methods s CD 44v6 and s CD 44 levels were measured in the sera of patients and healthy children by enzyme‐linked immunosorbent assay. The level of the molecules was analyzed in relation to laboratory and clinical characteristics of the patients at presentation and response to therapy. Result s CD 44v6 was significantly lower in patients (103.4 ± 44 ng/mL) than in controls (173.5 ± 73.6 ng/mL) whereas the serum level of s CD 44 showed no significant difference between the groups. In patients, s CD 44v6 quantity was inversely correlated with s CD 44 level ( r = −0.57, P < 0.01). The mean serum level of s CD 44 in patients with >20% positivity for CD 44 surface expression was greater than that in patients with ≤20% positivity (1345 ± 409 ng/mL vs 1111 ± 390 ng/mL, P = 0.05). s CD 44v6 showed no significant association with response to therapy and prognostic factors except the TEL / AML 1 positivity, as it was higher in TEL / AML 1 positive patients (157.3 ± 55.6 ng/mL) than negative ones (92 ± 43.6 ng/mL, P = 0.036). Conversely, s CD 44 was lower in TEL / AML 1 positive patients and showed a significant association with white blood cell number, blast percentage and extramedullary involvement. Conclusion The lower level of s CD 44v6 in patients than in controls suggests the possible diagnostic value of this molecule for B ‐ ALL . The presence of an association with established prognostic factors despite of no relationship with disease outcome suggested these molecules for more studies in larger patient cohorts.